Dolby Laboratories DLB
58.56
1.00
1.74%
as of 25 Sep
- Market cap
- $5.4B
- P/E
- 24.6×
Follow DLB
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 8.69% | 9.35% | 9.40% | 9.96% |
+8 more TTM periods Free account |
|
| 7.12% | 7.52% | 7.57% | 8.05% | ||
ROIC |
8.06% | 8.08% | 8.24% | 9.01% | |
Return on Tangible Assets |
16.52% | 17.38% | 16.80% | 17.95% | |
Average Days of Receivables |
76.85 | 104.64 | 101.71 | 89.58 | |
Free Cash Flow per Share |
3.83 | 2.78 | 4.05 | 4.49 | |
Free Cash Flow |
361.13 | 264.72 | 386.30 | 430.26 | |
Capital Expenditures |
(76.47) | (73.11) | (33.92) | (41.94) | |
Piotroski F-Score |
3.00 | 4.00 | 4.00 | 5.00 | |
| Other line items | |||||
Cash ROIC |
13.13% | 10.23% | 12.61% | 13.78% | |
Accounts Receivable Turnover |
4.65 | 3.87 | 3.76 | 4.17 | |
Accounts Payable Turnover |
11.30 | 9.03 | 16.08 | 9.09 | |
Inventory Turnover |
5.31 | 5.15 | 5.15 | 4.99 | |
Average Days of Payables |
27.13 | 44.04 | 19.46 | 40.66 | |
Days of Inventory on Hand |
66.94 | 67.97 | 70.20 | 69.35 | |
Tax Rate |
(0.18) | (0.15) | (0.16) | (0.15) | |
Research and Development Expense of Revenue |
19.64% | 19.50% | 19.74% | 19.40% | |
Selling, General and Administrative Expense of Revenue |
48.64% | 48.11% | 48.14% | 47.97% | |
Share Based Compensation of Revenue |
9.59% | 9.50% | 9.68% | 9.53% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.93 | 1.39 | 1.75 | 1.85 | |
Depreciation/Fixed assets |
0.23 | 0.22 | 0.21 | 0.21 | |
Capex/Depreciation |
(0.74) | (0.71) | (0.34) | (0.43) | |
Revenue per Share |
14.37 | 14.33 | 14.02 | 14.07 | |
Operating CF per Share |
4.64 | 3.55 | 4.40 | 4.93 | |
Capex per Share |
(0.81) | (0.77) | (0.36) | (0.44) | |
Capex to Sales |
0.06 | 0.05 | 0.03 | 0.03 | |
Net Profit Margin |
16.70% | 17.85% | 17.97% | 18.90% |
Columns are period end dates